AAD: Continuous Improvements Seen Through 68 Weeks for Deuruxolitinib in Alopecia

HealthDay News — For adults with alopecia areata, continuous improvements are seen through 68 weeks with deuruxolitinib, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 12 in San Diego.

Brett King, MD, PhD, from the Yale School of Medicine in New Haven, Connecticut, and colleagues reported pooled 68-week results from 2 open-label extension (OLE) trials of the THRIVE-AA1/AA2 trials. Participants in a qualifying study who completed 24 weeks of dosing with deuruxolitinib were eligible for OLE trials. Every 4 weeks for the first 12 weeks and every 8 weeks thereafter, the Severity of Alopecia Tool (SALT) score was measured.

The researchers found that from baseline, there was a decrease in the mean SALT scores in participants who received any dose of deuruxolitinib in qualifying studies and OLEs (86.8 to 26.8). The proportion of participants achieving a SALT score less than 20 was 34.9% at the conclusion of the qualifying study (week 24) and increased to 62.6% at week 68. Increasing efficacy was seen for both the 8mg and 12mg twice-daily doses with a last-observation-carried-forward (LOCF) imputation analysis and an as-observed (AO) analysis. The proportion of patients achieving a SALT score 20 or less at week 68 was 48.8 and 60.9% for 8mg and 12mg twice daily, respectively, for LOCF, and 76.6 and 66.7%, respectively, for AO.

“Scalp hair regrowth up to 68 weeks showed continuous, clinically meaningful improvements in adults with alopecia areata taking deuruxolitinib,” the authors write.

The THRIVE-AA1/AA2 trials were sponsored by Concert Pharmaceuticals, the manufacturer of deuruxolitinib.

More Information